Doh

G42 Healthcare and AstraZeneca Sign Agreement to Advance Life Sciences at BIO International Convention

Retrieved on: 
Tuesday, June 21, 2022
Solution, Oncology, Department of Health (Abu Dhabi), Department, AstraZeneca, Vaccines Manufacturing and Innovation Centre, Intelligence, United Arab Emirates, Health care, View, CEO, Research, Corporate Affairs, Letter, LOI, Doh, Emirate, Associate, Partnership, Patient, Cloud computing, Multimedia, Organization, Medical tourism, RWE, Pharmaceutical industry, G42

Witnessed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH, Hicham Mirghani, Corporate Affairs Director GCC at AstraZeneca and Dr. Fahed Al Marzooqi, Chief Operating Officer at G42 Healthcare, the agreement was signed by Ghaleb Al Ahdab Government Affairs, Associate Director Gulf at AstraZeneca, and Francesco Redivo Senior Director at G42 Healthcare during the BIO International Convention held in San Diego, California.

Key Points: 
  • Witnessed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH, Hicham Mirghani, Corporate Affairs Director GCC at AstraZeneca and Dr. Fahed Al Marzooqi, Chief Operating Officer at G42 Healthcare, the agreement was signed by Ghaleb Al Ahdab Government Affairs, Associate Director Gulf at AstraZeneca, and Francesco Redivo Senior Director at G42 Healthcare during the BIO International Convention held in San Diego, California.
  • G42 Healthcare and AstraZeneca initially signed a Declaration of Collaboration in December 2021.
  • Ashish Koshy, CEO of G42 Healthcare, said, "We value collaboration and believe the strategic partnership with AstraZeneca will yield incredible growth for the healthcare ecosystem.
  • Hicham Mirghani, Corporate Affairs Director GCC, AstraZeneca said, "We are excited about expanding our existing partnership with G42 Healthcare to further advance the healthcare sector in the country and region.

G42 Healthcare and AstraZeneca Sign Agreement to Advance Life Sciences at BIO International Convention

Retrieved on: 
Tuesday, June 21, 2022
Solution, Oncology, Department of Health (Abu Dhabi), Department, AstraZeneca, Vaccines Manufacturing and Innovation Centre, Intelligence, United Arab Emirates, Health care, CEO, Research, Corporate Affairs, Letter, LOI, Doh, Emirate, Associate, Partnership, Patient, Cloud computing, Organization, Medical tourism, RWE, Pharmaceutical industry, G42

Witnessed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH, Hicham Mirghani, Corporate Affairs Director GCC at AstraZeneca and Dr. Fahed Al Marzooqi, Chief Operating Officer at G42 Healthcare, the agreement was signed by Ghaleb Al Ahdab Government Affairs, Associate Director Gulf at AstraZeneca, and Francesco Redivo Senior Director at G42 Healthcare during the BIO International Convention held in San Diego, California.

Key Points: 
  • Witnessed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH, Hicham Mirghani, Corporate Affairs Director GCC at AstraZeneca and Dr. Fahed Al Marzooqi, Chief Operating Officer at G42 Healthcare, the agreement was signed by Ghaleb Al Ahdab Government Affairs, Associate Director Gulf at AstraZeneca, and Francesco Redivo Senior Director at G42 Healthcare during the BIO International Convention held in San Diego, California.
  • G42 Healthcare and AstraZeneca initially signed a Declaration of Collaboration in December 2021.
  • Ashish Koshy, CEO of G42 Healthcare, said, "We value collaboration and believe the strategic partnership with AstraZeneca will yield incredible growth for the healthcare ecosystem.
  • Hicham Mirghani, Corporate Affairs Director GCC, AstraZeneca said, "We are excited about expanding our existing partnership with G42 Healthcare to further advance the healthcare sector in the country and region.

G42 Healthcare and AstraZeneca Sign Agreement to Advance Life Sciences at BIO International Convention

Retrieved on: 
Tuesday, June 21, 2022
Solution, Oncology, Department of Health (Abu Dhabi), Department, AstraZeneca, Vaccines Manufacturing and Innovation Centre, Intelligence, United Arab Emirates, Health care, CEO, Research, Corporate Affairs, Letter, LOI, Doh, Emirate, Associate, Partnership, Patient, Cloud computing, Organization, Medical tourism, RWE, Pharmaceutical industry, G42

Witnessed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH, Hicham Mirghani, Corporate Affairs Director GCC at AstraZeneca and Dr. Fahed Al Marzooqi, Chief Operating Officer at G42 Healthcare, the agreement was signed by Ghaleb Al Ahdab Government Affairs, Associate Director Gulf at AstraZeneca, and Francesco Redivo Senior Director at G42 Healthcare during the BIO International Convention held in San Diego, California.

Key Points: 
  • Witnessed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH, Hicham Mirghani, Corporate Affairs Director GCC at AstraZeneca and Dr. Fahed Al Marzooqi, Chief Operating Officer at G42 Healthcare, the agreement was signed by Ghaleb Al Ahdab Government Affairs, Associate Director Gulf at AstraZeneca, and Francesco Redivo Senior Director at G42 Healthcare during the BIO International Convention held in San Diego, California.
  • G42 Healthcare and AstraZeneca initially signed a Declaration of Collaboration in December 2021.
  • Ashish Koshy, CEO of G42 Healthcare, said, "We value collaboration and believe the strategic partnership with AstraZeneca will yield incredible growth for the healthcare ecosystem.
  • Hicham Mirghani, Corporate Affairs Director GCC, AstraZeneca said, "We are excited about expanding our existing partnership with G42 Healthcare to further advance the healthcare sector in the country and region.

G42 Healthcare and AstraZeneca Sign Agreement to Advance Life Sciences at BIO International Convention

Retrieved on: 
Tuesday, June 21, 2022
Solution, Oncology, Department of Health (Abu Dhabi), Department, AstraZeneca, Vaccines Manufacturing and Innovation Centre, Intelligence, United Arab Emirates, Health care, CEO, Research, Corporate Affairs, Letter, LOI, Doh, Emirate, Associate, Partnership, Patient, Cloud computing, Organization, Medical tourism, RWE, Pharmaceutical industry, G42

Witnessed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH, Hicham Mirghani, Corporate Affairs Director GCC at AstraZeneca and Dr. Fahed Al Marzooqi, Chief Operating Officer at G42 Healthcare, the agreement was signed by Ghaleb Al Ahdab Government Affairs, Associate Director Gulf at AstraZeneca, and Francesco Redivo Senior Director at G42 Healthcare during the BIO International Convention held in San Diego, California.

Key Points: 
  • Witnessed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH, Hicham Mirghani, Corporate Affairs Director GCC at AstraZeneca and Dr. Fahed Al Marzooqi, Chief Operating Officer at G42 Healthcare, the agreement was signed by Ghaleb Al Ahdab Government Affairs, Associate Director Gulf at AstraZeneca, and Francesco Redivo Senior Director at G42 Healthcare during the BIO International Convention held in San Diego, California.
  • G42 Healthcare and AstraZeneca initially signed a Declaration of Collaboration in December 2021.
  • Ashish Koshy, CEO of G42 Healthcare, said, "We value collaboration and believe the strategic partnership with AstraZeneca will yield incredible growth for the healthcare ecosystem.
  • Hicham Mirghani, Corporate Affairs Director GCC, AstraZeneca said, "We are excited about expanding our existing partnership with G42 Healthcare to further advance the healthcare sector in the country and region.

The Department of Health - Abu Dhabi joins AstraZeneca's A.Catalyst network to attract and support start-ups globally

Retrieved on: 
Wednesday, June 15, 2022
Solution, Economic development, Department of Health (Abu Dhabi), Department, Drug development, AstraZeneca, Scottish Aquaculture Innovation Centre, View, Research, Corporate Affairs, Disease, Doh, Partnership, Multimedia, Awareness, SAN, Pharmaceutical industry

The partnership highlights DoH's commitment to enhancing digital healthcare in the emirate and improving patient experience and outcomes.

Key Points: 
  • The partnership highlights DoH's commitment to enhancing digital healthcare in the emirate and improving patient experience and outcomes.
  • In an effort to attract leading international healthcare start-ups to Abu Dhabi, DoH seeks to expand collaboration with AstraZeneca to cocreate an innovative ecosystem equipped with an advanced infrastructure.
  • The network focuses on bringing innovation to disease awareness, diagnostics, treatment wellness, and well-being to create a more holistic patient experience.
  • Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at the Department of Health Abu Dhabi (DoH), said: "Through this partnership, Abu Dhabi is further solidifying its position as a life sciences hub by focusing on healthcare innovation.

The Department of Health - Abu Dhabi joins AstraZeneca's A.Catalyst network to attract and support start-ups globally

Retrieved on: 
Wednesday, June 15, 2022
Solution, Economic development, Department of Health (Abu Dhabi), Department, Drug development, AstraZeneca, Scottish Aquaculture Innovation Centre, Research, Corporate Affairs, Disease, Doh, Partnership, Awareness, SAN, Pharmaceutical industry

The partnership highlights DoH's commitment to enhancing digital healthcare in the emirate and improving patient experience and outcomes.

Key Points: 
  • The partnership highlights DoH's commitment to enhancing digital healthcare in the emirate and improving patient experience and outcomes.
  • In an effort to attract leading international healthcare start-ups to Abu Dhabi, DoH seeks to expand collaboration with AstraZeneca to cocreate an innovative ecosystem equipped with an advanced infrastructure.
  • The network focuses on bringing innovation to disease awareness, diagnostics, treatment wellness, and well-being to create a more holistic patient experience.
  • Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at the Department of Health Abu Dhabi (DoH), said: "Through this partnership, Abu Dhabi is further solidifying its position as a life sciences hub by focusing on healthcare innovation.

The Department of Health - Abu Dhabi and MSD GCC Sign Declaration of Collaboration to Support Healthcare Advancement and Innovation in Abu Dhabi

Retrieved on: 
Wednesday, June 15, 2022
MSD, Abu Dhabi Investment Office, Solution, ADQ, Education, Department of Health (Abu Dhabi), Department, Public health, Collaboration, Khalifa University, Etihad Airways, Vaccine, Technology, Neuroscience, Innovation, View, Artificial intelligence, Leadership, Research, Adoption, GCC, Abu Dhabi Ports, ABU, Doh, Health, Emirate, Digital technology, Partnership, Patient, Diagnosis, Multimedia, Population health, Diabetes, Pharmaceutical industry, Management, Medicinal plants, Medicine

The collaboration is in alignment with Abu Dhabi's on-going efforts to position itself as a global leader in life sciences and an incubator for healthcare innovation.

Key Points: 
  • The collaboration is in alignment with Abu Dhabi's on-going efforts to position itself as a global leader in life sciences and an incubator for healthcare innovation.
  • The initiatives planned in the declaration of collaboration are aligned with the DoH's Abu Dhabi Healthcare Strategic Plan, and its mission to promote the Emirate of Abu Dhabi as a leading global life science and health technology hub.
  • The visit aims to lay down sustainable mechanisms that empower the healthcare sector in both countries as well as showcase Abu Dhabi's distinguished healthcare ecosystem.
  • The Abu Dhabi delegation to the US witnessed the participation of ten key entities in the life science ecosystem in Abu Dhabi including the Department of Health Abu Dhabi (DoH), Abu Dhabi Investment Office (ADIO), Mubadala Health, G42 Healthcare, Abu Dhabi Ports, ADQ, Etihad Cargo, Khalifa University, Hayat-vax and Pure Health.

The Department of Health - Abu Dhabi and MSD GCC Sign Declaration of Collaboration to Support Healthcare Advancement and Innovation in Abu Dhabi

Retrieved on: 
Wednesday, June 15, 2022
MSD, Abu Dhabi Investment Office, Solution, ADQ, Education, Department of Health (Abu Dhabi), Department, Public health, Collaboration, Khalifa University, Etihad Airways, Vaccine, Technology, Neuroscience, Innovation, Artificial intelligence, Leadership, Research, Adoption, GCC, Abu Dhabi Ports, ABU, Doh, Health, Emirate, Digital technology, Partnership, Patient, Diagnosis, Population health, Diabetes, Pharmaceutical industry, Management, Medicinal plants, Medicine

The collaboration is in alignment with Abu Dhabi's on-going efforts to position itself as a global leader in life sciences and an incubator for healthcare innovation.

Key Points: 
  • The collaboration is in alignment with Abu Dhabi's on-going efforts to position itself as a global leader in life sciences and an incubator for healthcare innovation.
  • The initiatives planned in the declaration of collaboration are aligned with the DoH's Abu Dhabi Healthcare Strategic Plan, and its mission to promote the Emirate of Abu Dhabi as a leading global life science and health technology hub.
  • The visit aims to lay down sustainable mechanisms that empower the healthcare sector in both countries as well as showcase Abu Dhabi's distinguished healthcare ecosystem.
  • The Abu Dhabi delegation to the US witnessed the participation of ten key entities in the life science ecosystem in Abu Dhabi including the Department of Health Abu Dhabi (DoH), Abu Dhabi Investment Office (ADIO), Mubadala Health, G42 Healthcare, Abu Dhabi Ports, ADQ, Etihad Cargo, Khalifa University, Hayat-vax and Pure Health.

Etihad Cargo Signs MOU for Sustainable Pharmaceutical Transportation Solutions

Retrieved on: 
Tuesday, June 14, 2022
Transport, Animal, ABU, SDD, WHO, Varian Medical Systems, Doh, Technology, Etihad Airways, Blood management, Sustainability, Center, Abu Dhabi Investment Office, Red, Partnership, Solution, International Red Cross and Red Crescent Movement, Emirate, Electrolux, UNICEF, MOU, Blood transfusion, IATA, Abu Dhabi Ports, Carbon, Khalifa University, Department of Health (Abu Dhabi), Ministry of Health and Medical Education, Temperature, Senior, HOPE, Vaccine, Hospital, Medication, Department, System, ADQ, Environment, Aviation, Atmosphere, Ministry, University, Pharmaceutical industry, Health

Etihad Cargo has signed an MOU with B Medical Systems to become the first airline globally to develop and launch sustainable, temperature-controlled containers for the transportation of pharmaceuticals and life sciences.

Key Points: 
  • Etihad Cargo has signed an MOU with B Medical Systems to become the first airline globally to develop and launch sustainable, temperature-controlled containers for the transportation of pharmaceuticals and life sciences.
  • ABU DHABI, United Arab Emirates, June 14, 2022 /PRNewswire/ --Etihad Cargo, the cargo and logistics arm of Etihad Aviation Group, has entered into a memorandum of understanding (MOU) with B Medical Systems.
  • Etihad Cargo will collaborate with Luxembourg-based manufacturer and global distributor of medical refrigeration devices, B Medical Systems, to develop more sustainable temperature-controlled container units that work utilising passive cooling technology.
  • Etihad Cargo is the cargo and logistics arm of the Etihad Aviation Group.

Etihad Cargo Signs MOU for Sustainable Pharmaceutical Transportation Solutions

Retrieved on: 
Tuesday, June 14, 2022
Transport, Animal, ABU, SDD, WHO, Varian Medical Systems, Doh, Technology, Etihad Airways, Blood management, Sustainability, Center, Abu Dhabi Investment Office, Red, Partnership, Solution, International Red Cross and Red Crescent Movement, Emirate, Electrolux, UNICEF, MOU, Blood transfusion, IATA, Abu Dhabi Ports, Carbon, Khalifa University, Department of Health (Abu Dhabi), Ministry of Health and Medical Education, Temperature, Senior, HOPE, Vaccine, Hospital, Medication, Department, System, ADQ, Environment, Aviation, Atmosphere, Ministry, University, Pharmaceutical industry, Health

Etihad Cargo has signed an MOU with B Medical Systems to become the first airline globally to develop and launch sustainable, temperature-controlled containers for the transportation of pharmaceuticals and life sciences.

Key Points: 
  • Etihad Cargo has signed an MOU with B Medical Systems to become the first airline globally to develop and launch sustainable, temperature-controlled containers for the transportation of pharmaceuticals and life sciences.
  • ABU DHABI, United Arab Emirates, June 14, 2022 /PRNewswire/ --Etihad Cargo, the cargo and logistics arm of Etihad Aviation Group, has entered into a memorandum of understanding (MOU) with B Medical Systems.
  • Etihad Cargo will collaborate with Luxembourg-based manufacturer and global distributor of medical refrigeration devices, B Medical Systems, to develop more sustainable temperature-controlled container units that work utilising passive cooling technology.
  • Etihad Cargo is the cargo and logistics arm of the Etihad Aviation Group.